The Orange County Register reports that the recruitment phase should be completed in February. According to information posted by Allergan on the National Institutes of Health’s ClinicalTrials.gov website, the trial’s initial phase will observe a group of 28 patients, comprising men with moderate male-pattern baldness and women with moderate female-pattern hair loss.
The Food and Drug Administration approved Latisse in 2008 for use in spurring eyelash growth. The Register reports that some doctors use Latisse off-label as a treatment for hair loss.
Latisse Eyelash Drug Baldness Cure, Baldness Cure
Comments